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Abstract
Streptococcus pneumoniae is a major cause of pneumonia, sepsis and meningitis. The
pore-forming toxin pneumolysin is a key virulence factor of S. pneumoniae, which can be
sensed by the NLRP3 inflammasome. Among the over 90 serotypes, serotype 1 pneumo-
cocci (particularly MLST306) have emerged across the globe as a major cause of invasive
disease. The cause for its particularity is, however, incompletely understood. We therefore
examined pneumococcal infection in human cells and a human lung organ culture system
mimicking infection of the lower respiratory tract. We demonstrate that different pneumococ-
cal serotypes differentially activate inflammasome-dependent IL-1β production in human
lung tissue and cells. Whereas serotype 2, 3, 6B, 9N pneumococci expressing fully haemo-
lytic pneumolysins activate NLRP3 inflammasome-dependent responses, serotype 1 and 8
strains expressing non-haemolytic toxins are poor activators of IL-1β production. Accord-
ingly, purified haemolytic pneumolysin but not serotype 1-associated non-haemolytic toxin
activates strong IL-1β production in human lungs. Our data suggest that the evasion of
inflammasome-dependent innate immune responses by serotype 1 pneumococci might
contribute to their ability to cause invasive diseases in humans.
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Introduction
Streptococcus pneumoniae is both a frequent colonizer of the human nasopharynx and a major
cause of invasive diseases. Depending on preceding viral infections, the immune status of the
host, and on the pneumococcal strain, an asymptomatic colonization can establish and progress
to pneumonia, sepsis, or meningitis [1,2]. These infections are associated with high morbidity
and mortality. It is estimated that S. pneumoniae causes over 1 million infant deaths every year
worldwide and probably even more in elderly people and immunocompromised patients [3].
The more than 90 capsular serotypes of S. pneumoniae vary markedly in their ability to
cause invasive infection. For example, serotypes 3, 6B, 9N and others are associated with naso-
pharyngeal colonization but also with infections in patients with underlying diseases, and with
higher mortality when causing pneumonia. In contrast, dominating clones of serotypes 1 and 8
are frequently found in invasive diseases that, however, show lower case-fatality rates [4–7].
Among serotype 1 pneumococci, the recently emerging MLST306 clone now dominates by
over 80% in many parts of the world [8–13]. While the degree of encapsulation positively asso-
ciates with colonization prevalence and virulence [5], other bacterial factors that affect the
interaction with the host´s innate immune system might also play a role.
In addition to the capsule, pneumolysin (PLY) is a major virulence factor of S. pneumoniae
[1,14]. PLY is a member of the cholesterol-dependent cytolysins expressed by various Gram-pos-
itive bacteria. PLY of most pneumococci binds to cholesterol-containing membranes, forms
pores upon oligomerization, and thereby causes cell lysis [15,16]. At sublytic concentrations, PLY
has been described to activate the complement system and to stimulate cytokine production in
monocytes and macrophages [1,14]. Moreover, PLY has been implicated in biofilm formation,
independent of its haemolytic activity [17]. Studies in mouse models of primary pneumococcal
pneumonia demonstrated that PLY-deficient strains are more rapidly cleared from the lungs and
induce less inflammation compared to isogenic toxin-producing bacteria [18–20]. Interestingly,
PLY exists in at least 16 different protein variants with variable haemolytic activity. For example,
allele 5 PLY expressed by serotype 1 MLST306 and some serotype 8 pneumococci is non-haemo-
lytic in contrast to the allele 1 PLY of the D39 strain [9,21,22].
Recent studies by us and others showed that the innate immune system can sense haemolytic
PLY through the canonical NLRP3 inflammasome [23–26]. Canonical inflammasomes are multi-
protein complexes mainly expressed in monocytes and macrophages. They are composed of a
receptor molecule belonging to the NOD-like receptor family (such as NLRP3) or the PYHIN
protein family (e.g. AIM2), the adapter molecule ASC and caspase-1 [27,28]. Inflammasomes
post-transcriptionally regulate the production of IL-1β and IL-18 by a caspase-1-dependent pro-
cessing of the cytokine pro-forms into mature cytokines, and induce an inflammatory cell death
called pyroptosis. Mice lacking inflammasome components or receptors for IL-1 or IL-18 show
an altered susceptibility towards S. pneumoniae [23–26,29,30], indicating that inflammasomes
are critical components of the innate defence system during pneumococcal infection.
Here we demonstrate that different pneumococcal strains are differentially recognized by
the innate immune system in human lung tissue. The NLRP3 inflammasome senses S. pneumo-
niae expressing haemolytic PLY in human lung tissue, whereas the pneumococcal serotypes 1
and 8 expressing non-haemolytic toxins are poor inflammasome activators.
Materials and Methods
Bacterial strains and PLYs
S. pneumoniae serotype 2 D39 and D39Δply have been described before [31,32]. S. pneumoniae
serotype 1 multi locus sequence type (MLST)306, serotype 3 MLST180, serotype 6B MLST176,
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serotype 8 MLST53 and serotype 9NMLST66 were kindly provided by the National Reference
Centre for Streptococci, Germany. Bacteria were grown in THY media at 37°C and 5% CO2
until they reached a phase of logarithmic growth. The PLY gene was amplified by PCR from
the appropriate strain and cloned into pET33b (Novagen) which results in addition of poly-
His tag to the N-terminus of the protein. The resulting construct was transformed into E. coli
BL21 for expression following manufactures instructions. Cell extracts were prepared by soni-
cation of cell pellets followed by clarification by centrifugation. PLY was purified by metal
affinity purification of the His-tagged protein following the manufacturer’s instructions. Purity
was confirmed by Coomassie Blue staining of proteins separated by SDS-PAGE.
Cells and infection
Human PBMCs were purified from buffy coats by gradient centrifugation as described previ-
ously [33]. Cells were infected with 1 x 106 (MOI = 1) or 1 x 104 (MOI = 0.01) CFU/mL S.
pneumoniae or treated with 10 μM Z-YVAD (Merck Millipore), allele 1 or allele 5 PLY (0.25,
0.5, 1 μg/ml).
Human lung tissue
Lung tissue samples were obtained from 33 patients primarily suffering from bronchial carci-
noma, which underwent lung resection at local thoracic surgeries, and prepared as described
previously [34,35]. Written informed consent was approved by all patients and the study was
approved by the ethic committee at the Charité clinic (protocol number EA2/050/08 and EA2/
023/07). For infection tumor-free normal lung tissue was injected with 200 μl of S. pneumoniae
106 CFU/mL per 100 μg tissue for 24 hours or treated with 100μM glybenclamide (Sigma-
Aldrich, St. Louis, MO, USA) 2 h before infection.
ELISA
IL-1β and IL-8 release was quantified by ELISA in cell-free and tissue-free supernatants
(eBioscience; BD Biosciences). Lactate dehydrogenase (LDH) release was quantified by Cyto-
Tox 96 Non-Radioactive Cytotoxicity Assay (Promega).
Quantitative PCR
For analysis of transcriptional Il1b regulation, total cellular RNA was isolated, transcribed to
cDNA, and amplified by quantitative RT-PCR using Gene Expression Master Mix and Il1b
TaqMan Gene Expression Assay (Applied Biosystems).
Haemolytic assay
Bacteria were lysed for 1 h at 4°C (5 mg/mL lysozyme (Sigma-Aldrich), 25 mM Tris-HCl, 50
mMNaCl, protease inhibitor cocktail (Roche)) followed by sonication. The cellular fraction of
human blood was PBS-washed, diluted in PBS (2%) and incubated with pneumococcal lysates
for 1 h at room temperature. After centrifugation, red blood cell lysis was assessed. The highest
amount of pneumococcal lysate used were generated from 5x106 CFU S. pneumoniae. Adjacent
wells in a row represent a 2-fold dilution.
Western blot
Proteins from human lung tissue were extracted using lysis buffer and disrupted in FastPrep-
24 homogenizer. Anti-IL-1beta, actin (Santa Cruz Biotechnology) and anti-NLRP3 (Adipogen)
antibodies were used. Proteins were detected by incubation with HRP-conjugated IgG
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antibodies (Santa Cruz Biotechnology) and Pierce ECLWestern Blotting Substrate (Thermo
Scientific).
Comparative protein modelling of PLY
Three-dimensional protein structure of allele 5 PLY was built by comparative modelling using
the MODELLER 9.11 software [36]. The crystal structure of perfringolysin O (PDB: 1PFO) was
used as a template for modelling [37].
Sequencing of bacterial strains
S. pneumoniae serotypes (1, 3, 6B, 8 and 9N) were genome sequenced as described below using
Illumina’ MiSeq next generation sequencing system. Chromosomal DNA was isolated using
PureLink Genomic DNAMini Kit (Life Technologies). Nextera XT paired-end library was pre-
pared and sequenced on a MiSeq using v3 chemistry, according to protocols recommended by
the manufacturer (Illumina). Sequencing reads were assembled using SPades [38] and contigs
were ordered by r2cat [39] using S. pneumoniae D39 genome (accession number NC_008533)
as reference genome. Draft genome sequences were submitted to the GenDB annotation system
[40]. Finally, pneumolysin DNA sequences for each S. pneumoniae serotype were provided by
GenDB, whereas draft genome sequence reads will be used for further comparative genomic
analysis.
Data Analysis
Data are expressed as mean ± SEM. Samples were tested for a normal distribution with the
D’Agostino and Pearson Omnibus Normality Test. Statistical analysis of normally distributed
samples was performed using ANOVA followed by a Bonferroni post-hoc test and samples
that were not normally distributed were analysed with Kruskal–Wallis test followed by Dunn’s
multiple comparison test. The Mann-Whitney U Test was used for the comparison of two pop-
ulations. Data analysis was performed using the Prism software (GraphPad Software, La Jolla,
CA). For all statistical analyses, p values< 0.05 were considered significant: p< 0.05,
p< 0.01, p< 0.001.
Results
S. pneumoniae serotypes with variable haemolytic activities differentially stimulate caspase-
1-dependent production of IL-1β by human cells.
To confirm that production of IL-1ß by human cells is dependent on PLY and on conven-
tional inflammasomes, we infected human PBMCs with S. pneumoniae serotype 2 expressing
haemolytic allele 1 PLY (D39) or with the isogenic mutant lacking PLY (D39Δply) and tested
the effect of a caspase-1 inhibitor. We found that only S. pneumoniae expressing PLY stimu-
lated strong IL-1β production, whereas the PLY-negative mutant induced only small amounts
of IL-1β (Fig 1A). In contrast, transcriptional regulation of Il1bmRNA and production of the
inflammasome-independent chemokine IL-8 was not affected by the lack of PLY (Fig 1B and
1C). Moreover, IL-1β but not IL-8 secretion was strongly reduced by treatment with the cas-
pase-1 inhibitor Z-YVAD (Fig 1D and 1E). These data are in line with previously published
studies and show that pneumococcal PLY is recognized by a conventional caspase-1-dependent
inflammasome to stimulate IL-1β production [23,24].
Next, we investigated the ability of different pneumococcal strains to induce haemolysis
and IL-1β production. S. pneumoniae serotypes 3, 6B, and 9N induced red blood cell lysis, indi-
cating expression of a haemolytic PLY (Fig 1F). In contrast, serotypes 1 and 8, expressing a
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non-haemolytic PLY, exhibited no haemolytic activities, as shown before (Fig 1F) [21].
Sequencing of the ply gene confirmed the expression of an allele 5 PLY in serotype 1 and 8 bac-
teria, and demonstrated that serotype 3, 6B and 9N express haemolytic allele 1 or 2 PLY
(Table 1). Allele 5 PLY possesses several mutations in the protein domain D3 (Fig 1G), which
is suggested to insert into the host cell membrane after conformational changes and is therefore
crucial for the pore-forming ability of PLY [41]. In accordance, only serotype 6B and 9N stimu-
lated a strong IL-1β production in human PBMCs, whereas serotypes 1 and 8 did not (Fig 1H).
Unexpectedly, serotype 3 was also a rather weak inducer of IL-1β production. This suggests
that other factors than PLY, such as perhaps an extensive capsule production of serotype 3
pneumococci, affect the innate sensing of the bacteria. All tested bacteria induced the transcrip-
tional regulation of Il1bmRNA (Fig 1I) and equally stimulated production of the inflamma-
some-independent chemokine IL-8 (Fig 1J). Moreover, cell death induced by S. pneumoniae
D39 was dependent on PLY (Fig 1K), and correlated with expression of haemolytic PLY (Fig
1L). Accordingly, purified allele 1 PLY induced a much stronger cell death as compared to
allele 5 PLY in humans cells (Fig 1M). Collectively, the data confirm and extend previously
published results [24], and demonstrate that pneumococcal strains expressing diverse toxins
induce different amounts of IL-1β production and cell death.
The production of IL-1β in S. pneumoniae-infected human lung tissue is
dependent on PLY and caspase-1
Next, we tested if the S. pneumoniae-induced production of IL-1β in human lungs is also
dependent on PLY and caspase-1. We found that S. pneumoniae D39 but not D39Δply stimu-
lated strong IL-1β production in human lung tissue (Fig 2A and 2B). In contrast, both strains
induced expression of Il1bmRNA and proIL-1β protein (Fig 2C and 2D). Inhibition of cas-
pase-1 by the specific inhibitor Z-YVAD reduced the pneumococci-induced production of IL-
Fig 1. S. pneumoniae serotypes differentially induce PLY- and caspase-1-dependent production of IL-1β by PBMCs as well as cell death. (A-C, H-L)
PBMCs were infected with S. pneumoniae strains (MOI = 1) as indicated or (D, E) were infected with S. pneumoniae D39 (MOI = 0.01) and treated with 10 μM
Z-YVAD. Production of IL-1β (A, D, H) and IL-8 (C, E, J) was quantified by ELISA after 16 h. (D, E) 100% were defined as the amount of IL-1β or IL-8 released
by S. pneumoniae-infected PBMCs. (B, I) Relative expression of Il1b was determined by quantitative RT-PCR after 5 h. (F) Human blood was incubated with
pneumococcal lysates of S. pneumoniae serotypes 3, 6B, 7F, 9N, 1 and 8, and haemolytic activity was assessed. (G) Comparative protein model of allele 5
PLY. PLY domains are colour coded and mutations are marked in rose. (K) PBMCs were infected with S. pneumoniaeD39 and D39Δply. (L) PBMCs were
infected with serotypes 3, 6B, 7F, 9N, 1 and 8 pneumococci. (M) PBMCs were stimulated with allele 1 and allele 5 PLY for 16 h. (K-M) LDH release was
quantified by cytotoxicity assay. Data are shown as mean ± SEM of three (D, E, M), five (B, I) or seven (A, C, H, J, K, L) independent experiments carried out
in duplicates or triplicates. Significance is indicated by asterisks * = p<0.05, ** = p<0.01, *** = p<0.001.
doi:10.1371/journal.pone.0137108.g001
Table 1. Pneumolysin allele determination by sequencing of ply genes was performed from the 6 isolates used in this study. The first row refers to
amino acid positions. The second row shows allele 1 PLY expressed in S. pneumoniae D39 [21]. The amino acid polymorphisms in the clinical isolates are
highlighted. Deletion of an amino acid is represented by the abbreviation DEL. Serotype 1 and 8 pneumococci express an allele 5 PLY as previously shown
[21].
Serotype MLST Allele Amino acid position
150 172 224 265 270 271 380
2 (D39) MLST128 1 Y T K A V K D
6B MLST176 1 Y T K A V K D
1 MLST306 5 H I R S DEL DEL D
8 MLST53 5 H I R S DEL DEL D
3 MLST180 2 Y T K A V K N
9N MLST66 2 Y T K A V K N
doi:10.1371/journal.pone.0137108.t001
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1β (Fig 2E). Thus, production of IL-1β in S. pneumoniae-infected human lung tissue is depen-
dent on PLY and inflammasomes.
The polymorphism in PLY affects production of IL-1β in human lung
tissue
We then infected human lung tissue with different haemolytic (serotypes 3, 6B, 9N) and
non-haemolytic (serotypes 1, 8) pneumococcal strains. We found that only the haemolytic S.
pneumoniae strains significantly induced IL-1β production in human lungs, whereas the non-
haemolytic serotype 1 and 8 bacteria did not (Fig 3A). Accordingly, haemolytic allele 1 PLY
stimulated a much stronger IL-1β production in human lungs as compared to non-haemolytic
allele 5 toxin (Fig 3B). These data indicate that the polymorphism in PLY also affects produc-
tion of IL-1β in human lung tissue. The serotype 1 and 8 bacteria expressing a non-haemolytic
PLY appear to evade recognition by inflammasomes, and therefore induce little IL-1β
production.
Production of IL-1β in S. pneumoniae-infected human lungs is
dependent on NLRP3
Finally, we tested if IL-1ß production in S. pneumoniae-infected human lung tissue is depen-
dent on NLRP3. We first checked expression of NLRP3 in the tissue and found up-regulation
Fig 2. The production of IL-1β in S. pneumoniae-infected human lung tissue is dependent on PLY and
caspase-1. (A-E) Human lung tissue was infected with 1x106 CFU/mL S. pneumoniae serotype 2 D39 or
D39Δply and treated with 100 ng/ml Z-YVAD 1 hour before infection where indicated. After 24 h, production of
IL-1β (A, B, E) was quantified by ELISA, relative expression of Il1bwas determined by qRT-PCR (C), or
expression of pro-IL-1β was assessed by immunoblotting (D). Data are shown as mean ± SEM of three (A),
five (E) or six (B, C) independent experiments carried out in duplicates. (D) One representative of four
independent experiments is shown. Significance is indicated by asterisks ** = p<0.01, *** = p<0.001.
doi:10.1371/journal.pone.0137108.g002
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of NLRP3 upon S. pneumoniaeD39 and D39Δply infection (Fig 4A and 4B). Second, we treated
the lung tissue with the inhibitor Glibenclamid. Glibenclamid blocks potassium channels that
are required for NLRP3 inflammasome activation [42], and is therefore frequently used as a
specific NLRP3 inflammasome inhibitor [43]. We found that inhibition of NLRP3 strongly
reduced the S. pneumoniae-induced IL-1β production (Fig 4C). Together, these data indicate
that the NLRP3 inflammasome mediates IL-1β production upon S. pneumoniae infection by
detecting haemolytic PLY in human lung tissue.
Fig 4. NLRP3 expression is up-regulated in human lung tissue during S. pneumoniae infection. (A, B) Human lung tissue was infected with 1x106
CFU/mL S. pneumoniae serotype 2 D39 or D39Δply and expression of NLRP3 was assessed by immunoblotting. (C) NLRP3 inhibitor glybenclamide
efficiently reduced IL-1β secretion in human lung tissue during S. pneumoniae infection. Human lung tissue was preincubated with the inhibitor for 2 h and
infected with 1x106 CFU/mL S. pneumoniaeD39 for 16 h. IL-1β production was quantified by ELISA. Data are shown as mean ± SEM of three (A, B) or six (C)
independent experiments carried out in duplicates. Significance is indicated by asterisks *** = p<0.001.
doi:10.1371/journal.pone.0137108.g004
Fig 3. Pneumococci expressing haemolytic but not non-haemolytic PLY stimulate IL-1β production in
human lung tissue. (A) Human lung tissue was infected with 1x106 CFU/mL S. pneumoniae serotypes 3,
6B, 9N, 1 and 8, or (B) were stimulated with 1μg/ml allele 1 and allele 5 PLY for 24 h. IL-1β secretion was
quantified by ELISA. Data are shown as mean ± SEM of eight (A) or six (B) independent experiments carried
out in duplicates. Significance is indicated by asterisks *** = p<0.001.
doi:10.1371/journal.pone.0137108.g003
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Discussion
The NLRP3 inflammasome is an important mediator of innate immunity during pneumococ-
cal pneumonia. It senses pneumococcal PLY in murine macrophages and mediates production
of the key inflammatory cytokines IL-1β and IL-18 [23,24]. Accordingly, mice deficient in
inflammasome components or receptors for IL-1 or IL-18 show an altered susceptibility
towards S. pneumoniae [23–25,29,30]. Although rodents, and in particular mice, are widely
used in biomedical research, increasing evidence suggests that some mechanisms and pathways
of the immune system differ between rodents and humans. It is therefore important to prove
the relevance of mechanisms that have been identified in murine models in human-relevant
systems. In this study, we used an ex vivo explant model allowing for the investigation of bacte-
rial [34] and viral infections in human lung tissue [44,45]. We demonstrate that the detection
of PLY by the NLRP3 inflammasome is also critically involved in the production of IL-1ß in
human lung tissue. Furthermore, various pneumococcal strains expressing natural PLY vari-
ants differentially induce inflammasome-dependent IL-1β production by human cells and lung
tissue.
PLY is a major virulence factor of S. pneumoniae that exhibits a wide variety of activities
consistent with virulence [14–16,46,47]. It is cytotoxic to host cells, inhibits ciliary beating on
the respiratory epithelium, activates the classical complement system, and stimulates inflam-
masomes [14]. Accordingly, bacterial mutants lacking PLY have been shown to be more rap-
idly cleared from the lungs compared to wild-type bacteria [18–20]. It is, however, less clear
which of the different activities of PLY contribute most to pneumococcal virulence.
The MLST306 serotype 1 clone has emerged as being responsible for over 80% of serotype 1
diseases in many parts of the world, and has been associated with invasive pneumococcal dis-
ease outbreaks [9,10,12,13]. MLST306 pneumococci express allele 5 PLY which differs in a few
amino acids from haemolytic allele 1 PLY and lacks any haemolytic activity but retains the abil-
ity to bind to cholesterol-containing membranes [9,21]. The expression of a non-haemolytic PLY
might make serotype 1 bacteria less damaging and harmful for the host, and possibly helps to
explain why serotype 1 diseases are associated with lower case fatality rates compared to other
pneumococcal infections [5]. However, not all serotype 1 pneumococci carry the non-haemolytic
PLY [21], and further studies are clearly required to prove or disprove this hypothesis.
A recent study compared isogenic mutants in the D39 background and showed that
mutants expressing allele 5 PLY exhibited a medium-level virulence compared to bacteria
expressing haemolytic PLY or lacking any toxin expression [48]. Taken this fact together with
epidemiological data might indicate that cytolytic activity is not an essential characteristic of
pneumococci for being virulent. Non-cytolytic properties of PLY are at least similarly impor-
tant. Moreover, the different activities of PLY might be even less essential for secondary pneu-
mococcal pneumonia following influenza virus infection [49].
We suggest that MLST306 serotype 1 might actually take advantage of expressing a non-
haemolytic toxin variant. The expression of allele 5 PLY enables serotype 1 pneumococci
to avoid the detection by inflammasomes and to minimize the production of key pro-inflam-
matory cytokines. We speculate that the evasion of inflammasome-dependent detection by
serotype 1 contributes to its ability to invade sterile compartments. Of note, expression of
haemolytic PLY has additionally been shown to be required for the detection of pneumococcal
peptidoglycan by NOD2 and DNA by a STING dependent pathway, respectively [47,50–52].
Avoiding recognition by those pathways might thus also add to the relative particularity of
serotype 1 pneumococci. Potentially in line with this assumption, serotype 1 pneumococci
appear to be weak inducers of Il1bmRNA (Fig 1I). Moreover, it is likely that other PLY-inde-
pendent characteristics of this strain such as e.g. capsule or cell wall composition influence the
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interaction with the host´s innate immune system. For example, we recently showed that sero-
type 1 bacteria differ to other serotypes in their binding to the C-type lectin receptor Mincle
[53].
Taken together, we demonstrate that different pneumococcal serotypes differentially acti-
vate the NLRP3 inflammasome in human lung tissue, and that important serotype 1 and 8
clones evade recognition by this central innate immune sensing mechanism. It will be impor-
tant to further dissect the contribution of this innate immune evasion to the pathogenic poten-
tial of these globally emerging bacterial strains.
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